A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer
Andrew W. Chung, Kartik Anand, Ann C. Anselme, Alfred A. Chan, Nakul Gupta, Luz A. Venta, Mary R. Schwartz, Wei Qian, Yitian Xu, Licheng Zhang, John G. Kuhn, Tejal Patel, Angel Rodriguez, Anna Belcheva, Jorge Darcourt, Joe Ensor, Eric Bernicker, Ping‐Ying Pan, Shu‐Hsia Chen, Delphine J. Lee, Polly Niravath, Jenny C. Chang
Abstract
neutrophils in blood, as well as a decrease in arginase (a marker of protumor N2 neutrophils) in tumor biopsies obtained at the end of treatment. L-NMMA combined with taxane warrants further investigation in larger clinical studies of patients with breast cancer.
Topics & Concepts
MedicineTaxaneBreast cancerTriple-negative breast cancerChemotherapyInternal medicinePhases of clinical researchOncologyDocetaxelCancerImmune cells in cancerCancer, Hypoxia, and MetabolismCancer, Stress, Anesthesia, and Immune Response